TCM
CDTX

TCG Crossover Management’s Cidara Therapeutics CDTX Stock Holding History

TCG Crossover Management’s Portfolio CDTX Stock Details CDTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-1,005,901
Closed -$49M – 43
2025
Q2 		$49M Hold
1,005,901
– – 5.6% 5
2025
Q1 		$21.7M Hold
1,005,901
– – 2.96% 14
2024
Q4 		$26.1M Buy
+1,005,901
New +$16.3M 2.55% 18

Other funds holding CDTX

RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
BCLSI
Bain Capital Life Sciences Investors Boston, Massachusetts $1.68B AUM 126.09% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.1B AUM 799.93% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
DGM
Darwin Global Management St. Helier, Jersey $3.76B AUM 342.13% 1-Year Est. Return
PBA
Paradigm Biocapital Advisors New York $5.34B AUM 380.18% 1-Year Est. Return
VA
VR Adviser New York $3.3B AUM 525.74% 1-Year Est. Return

TCG Crossover Management's CDTX Position: Q3 2025 in Review

TCG Crossover Management sold out of Cidara Therapeutics (CDTX) in Q3 2025, closing a stake of 1,005,901 shares — an estimated $49M sold.

TCG Crossover Management first reported a position in CDTX in Q4 2024 and held it in 3 quarters. The position peaked at $49M in Q2 2025. 173 funds tracked by Wall St. Rank hold CDTX as of Q3 2025.

  • TCG Crossover Management reported no remaining Cidara Therapeutics position as of Q3 2025 after selling out during the quarter.
  • TCG Crossover Management sold 1,005,901 Cidara Therapeutics shares in Q3 2025, an estimated $49M.
  • TCG Crossover Management first reported a position in Cidara Therapeutics in Q4 2024 and held it in 3 quarters.
  • TCG Crossover Management's Cidara Therapeutics position peaked at $49M in Q2 2025.
  • 173 funds tracked by Wall St. Rank held Cidara Therapeutics as of Q3 2025.

Based on TCG Crossover Management's 13F filing for Q3 2025, filed 17 Nov 2025.